Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Hypertension Research
  • View all journals
  • Search
  • Log in
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. hypertension research
  3. original article
  4. article
Informed Consent in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial: A Survey of Collaborating Physicians
Download PDF
Download PDF
  • Original Article
  • Published: 01 July 2006

Informed Consent in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial: A Survey of Collaborating Physicians

  • Tsuguya Fukui1,
  • Mahbubur Rahman1,
  • Satoshi Morita2 &
  • …
  • Junichi Sakamoto2 

Hypertension Research volume 29, pages 471–474 (2006)Cite this article

  • 605 Accesses

  • Metrics details

Abstract

An anonymous postal survey was conducted among the physicians collaborating in a randomized controlled trial to examine their method of convincing patients, their consent process, the factors related to higher accrual, and the predictors of 100% success in the process of obtaining informed consent (IC). A total of 512 questionnaires were sent out and 448 responses were received, for a response rate of 87.5%. The 448 physicians solicited a total of 5,371 eligible patients (12.0 per physician), among which 3,763 patients (8.4 per physician) agreed to participate. One-fifth (22.3%) of the physicians were able to obtain IC from 100% of the patients they solicited. Physicians who thought that the information on the IC sheet was sufficient to obtain consent (odds ratio [OR]=2.0, 95% confidence interval [CI]=1.1–3.9; p=0.03) and those who did not consider that the patient's decision was influenced by relatives and friends (OR=0.2, CI=0.1–0.4; p=0.001), were significantly more likely to obtain IC from 100% of the eligible patients. Three-fourths (73.2%) of the physicians targeted only patients who they perceived would easily provide IC, and 81.2% favored some form of incentives for patients. The results of this study should be useful for efficiently implementing randomized controlled trials in Japan.

Similar content being viewed by others

Canadian provider perspectives on Collagenase Clostridium histolyticum for the treatment of Peyronie’s disease and the impact of its discontinuation

Article 15 July 2021

Post-intensive care syndrome and health-related quality of life in long-term survivors of cardiac arrest: a prospective cohort study

Article Open access 08 May 2024

Factors associated with physician decision making on withholding cardiopulmonary resuscitation in prehospital medicine

Article Open access 04 March 2021

Article PDF

References

  1. Verheggen FW, van Wijmen FC : Myth and reality of informed consent in clinical trials. Med Law 1997; 16: 53–69.

    CAS  PubMed  Google Scholar 

  2. Lavori PW, Sugarman J, Hays MT, Feussner JR : Improving informed consent in clinical trials: a duty to experiment. Control Clin Trials 1999; 20: 187–193.

    Article  CAS  Google Scholar 

  3. Lavelle-Jones C, Byrne DJ, Rice P, Cuschieri A : Factors affecting quality of informed consent. BMJ 1993; 306: 885–890.

    Article  CAS  Google Scholar 

  4. Fukui T, Rahman M, Hayashi K, et al: Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients. Rationale, design and methods. Hypertens Res 2003; 26: 979–990.

    Article  CAS  Google Scholar 

  5. STATA Corporation : STATA Statistical Software Version 7.0 (Intercooled). College Station, STATA Corporation.

  6. Rahman M, Morita S, Fukui T, Sakamoto J : Physicians' choice in using internet and fax for patient recruitment and follow up in a randomized controlled trial. Methods Inform Med 2004; 43: 288–292.

    Google Scholar 

  7. Rahman M, Morita S, Fukui T, Sakamoto J : Physicians' attitude towards and reasons for participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. J Epidemiol 2005; 15: 38–40.

    Article  Google Scholar 

  8. Feld AD : Informed consent: not just for procedures anymore. Am J Gastroenterol 2004; 99: 977–980.

    Article  Google Scholar 

  9. Anonymous : Survey on physicians, dentists, and pharmacist. J Health Welfare Stat 2002; 9: 472 ( in Japanese).

  10. Anonymous : Health care manpower. J Health Welfare Stat 2002; 9: 170–183 ( in Japanese).

Download references

Author information

Authors and Affiliations

  1. Clinical Practice Evaluation and Research Center, St. Luke's Life Science Institute, St. Luke's International Hospital, Tokyo, Japan

    Tsuguya Fukui & Mahbubur Rahman

  2. Department of Epidemiological and Clinical Research Information Management, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Satoshi Morita & Junichi Sakamoto

Authors
  1. Tsuguya Fukui
    View author publications

    Search author on:PubMed Google Scholar

  2. Mahbubur Rahman
    View author publications

    Search author on:PubMed Google Scholar

  3. Satoshi Morita
    View author publications

    Search author on:PubMed Google Scholar

  4. Junichi Sakamoto
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Tsuguya Fukui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fukui, T., Rahman, M., Morita, S. et al. Informed Consent in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial: A Survey of Collaborating Physicians. Hypertens Res 29, 471–474 (2006). https://doi.org/10.1291/hypres.29.471

Download citation

  • Received: 28 January 2005

  • Accepted: 30 March 2005

  • Issue date: 01 July 2006

  • DOI: https://doi.org/10.1291/hypres.29.471

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • informed consent
  • randomized controlled trial
  • collaborating physicians
  • patient recruitment
  • Candesartan Antihypertensive Survival Evaluation in Japan
Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open Access Fees and Funding
  • Guide to Authors
  • About the Editors
  • Message from Editors
  • Call for Paper
  • Contact
  • About the Partner
  • For Advertisers
  • Subscribe
  • Showcase of Graphical Abstracts on Hypertension Research

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Hypertension Research (Hypertens Res)

ISSN 1348-4214 (online)

ISSN 0916-9636 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited